SP 5

Simulation of combination therapies

Targeted drugs can be designed to engage in signalling pathways, altering the flow of molecular information. This can lead to reprogramming of lymphoma cells, rebuilding the lymphoma microenvironment/stroma, or increasing the effectiveness of other drugs.  Often multiple drugs are combined. Here we develop pathway models to design combination therapies.

A model of a stroma induced signalling pathway in lymphomas. In red a selection of inhibitors is shown, which can be used to affect the signal flow.